Systemic immunosuppression promotes survival and integration of subretinally implanted human ESC-derived photoreceptor precursors in dogs

Ripolles-Garcia, A., N. Dolgova, M. Phillips, S. Savina, A. Ludwig, S. Stuedemann, U. Nlebedum, J. Wolfe, O. Garden, A. Maminishkis, J. Amaral, K. Bharti, D. Gamm, G. Aguirre, and W. Beltran. Systemic Immunosuppression Promotes Survival and Integration of Subretinally Implanted Human ESC-Derived Photoreceptor Precursors in Dogs. Stem Cell Reports, 2022, p. PubMed Text.

Abstract

Regenerative therapies aimed at replacing photoreceptors are a promising approach for the treatment of otherwise incurable causes of blindness. However, such therapies still face significant hurdles, including the need to improve subretinal delivery and long-term survival rate of transplanted cells, and promote sufficient integration into the host retina. Here, we successfully delivered in vitro-derived human photoreceptor precursor cells (PRPCs; also known as immature photoreceptors) to the subretinal space of seven normal and three rcd1/PDE6B mutant dogs with advanced inherited retinal degeneration. Notably, while these xenografts were rejected in dogs that were not immunosuppressed, transplants in most dogs receiving systemic immunosuppression survived up to 3-5 months postinjection. Moreover, differentiation of donor PRPCs into photoreceptors with synaptic pedicle-like structures that established contact with second-order neurons was enhanced in rcd1/PDE6B mutant dogs. Together, our findings set the stage for evaluating functional vision restoration following photoreceptor replacement in canine models of inherited retinal degeneration.

Keywords: canine models; fluorescence live imaging; hESC-PRPCs; immunosuppression; photoreceptor precursor; retinal degeneration; retinal organoid.